UK markets closed

Reneo Pharmaceuticals, Inc. (RPHM)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.7500+0.0900 (+5.42%)
At close: 04:00PM EDT
1.6900 -0.06 (-3.43%)
After hours: 07:22PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.6600
Open1.6100
Bid1.7300 x 400
Ask1.7800 x 100
Day's range1.6100 - 1.7600
52-week range0.9800 - 9.4500
Volume204,823
Avg. volume277,076
Market cap58.486M
Beta (5Y monthly)0.23
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Insider Monkey

    These Stocks under $10 Are Poised To Explode

    In this piece, we will take a look at these stocks under $10 are poised to explode. If you want to skip our introduction to these tricky stocks, jump to These 5 Stocks Under $10 Are Poised To Explode. The US equity markets remain on track for a strong finish in 2023 as major indices […]

  • Zacks

    Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Study

    Reneo (RPHM) loses 83% following the failure of the mid-stage pivotal study of its only pipeline candidate, mavodelpar, to treat primary mitochondrial myopathies in adults. It cuts the workforce by 70%.

  • Benzinga

    Why Is Genetic Disease Focused Reneo Pharmaceuticals Stock Plummeting Today?

    Reneo Pharmaceuticals Inc (NASDAQ: RPHM) shares are sinking after the company released data from its pivotal STRIDE Phase 2b study of mavodelpar in adult patients with primary mitochondrial myopathies (PMM), a group of mitochondrial diseases that cause prominent muscular problems. The study did not meet its primary efficacy or secondary efficacy endpoint. The trial's primary efficacy endpoint was the change from baseline in the distance walked during the 12-minute walk test (12MWT) at week 24. T